吲哚胺2，3双加氧酶与肿瘤免疫耐受  

Indoleamine 2,3-dioxygenase and immune tolerance in tumor

作　　者：卜晓倩(综述)[1] 王琦(审校)[1] 

机构地区：[1]山西医科大学第二医院消化内科,太原030012

出　　处：《国际肿瘤学杂志》2010年第4期276-278,共3页Journal of International Oncology

摘　　要：调节性T细胞（Treg）介导的克隆抑制，是引起肿瘤免疫耐受的主要因素之一。而吲哚胺2，3双加氧酶（IDO）通过对Treg细胞的作用下调各系统肿瘤微环境中的免疫反应，从而诱导宿主免疫耐受的形成。IDO抑制剂1-MT将有望成为治疗肿瘤的新靶点。Clonal suppression induced by CD4 ^＋ CD25 ^＋ regulatory T cells is one of the principal factors to evoke the immune tolerance in tumor. Through the activation of CD^4＋ CD25 ^＋ regulatory T cells, the indoleamine 2,3-dioxygenase （IDO） reduces the immune response in tumor micro-environment of various systems, and induces the formation of host immune tolerance. IDO inhibitor 1 - MT is expected to become a new target for cancer treatment.

关 键 词：肿瘤 免疫耐受 吲哚胺-吡咯2 3-双加氧酶 CD4^+CD25^+T细胞 

分 类 号：R730.51[医药卫生—肿瘤]